Register for free and gain unlimited access to our extensive elearning library
Earn CME points and track your learning activity with hundreds of hours of continuing medical education.
Share :

Angiogenesis in Gastric Cancer

This e-learning module aims to educate medical practitioners on the latest emerging evidence in the optimal integration of anti-angiogenic therapy in the treatment plan for gastric cancer patients which can then be applied in clinical practice. The information in this module is based on information presented at the Angiogenesis: Latest Developments in Gastric Cancer event at 25th March, 2015 in Milan, Italy.

Published in July 2015.

For more information, please contact

Angiogenesis in Gastric Cancer
0 CME Points

Target audience

This module is for medical practitioners with an interest in gastric cancer.

Learning objectives

By the end of the module, you should be able to:

• Understand the mechanisms and biology behind angiogenesis.
• Understand which biomarkers to select pre and post treatment.
• Understand which drugs, antibodies or combinations to use and when.
• Understand which patients would benefit from the latest developments.
• Understand the latest clinical trials in gastric cancer.

IT Requirements

This module requires the learner to have a good, stable internet connection and runs best on INTERNET EXPLORER 7 AND ABOVE, and MOZILLA FIREFOX on either Windows or MacOS. FLASH ADD ON is also required to run this module.

If you are viewing this module on an iPad (through a browser), please download the free Articulate Mobile Player beforehand. Other tablet devices may not be compatible - please check for Flash compatibility.

If you are experiencing technical difficulties, please contact and we will get back to you as soon as possible.

Disclosure policy

ecancer and Prof Gordon McVie have no actual or potential conflict of interest whatsoever which impinges on the making, peer reviewing and dissemination of this e-learning module which was made possible with support from Lilly Oncology and Beckman Coulter Life Sciences.